Syncom Formulations (India) Ltd Financials
Company Logo

Syncom Formulations (India) Ltd Financial Statement

Syncom Formulations (India) Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue155.37
Operating Expense130.99
Net Profit17.50
Net Profit Margin11.26
Earning Per Share0.16
EBIDTA23.38
Effective Tax Rate18.46

Syncom Formulations (India) Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual258.36
Operating Expenses Annual230.51
Operating Profit Annual40.93
Interest Annual4.45
Depreciation4.72
Net Profit Annual23.62
Tax Annual8.14

Syncom Formulations (India) Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.83
Cash Flow from Operations-5.94
Cash Flow from Investing83.83
Cash Flow from Financing-15.37
Cash Flow at the End63.35

Syncom Formulations (India) Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)15.94
PBIT Margin (%)14.11
PBT Margin (%)11.11
Net PROFIT Margin (%)9.14
Return On Networth / Equity (%)8.71
Return On Networth /Employed (%)10.32
Return On Assets (%)6.67
Total Debt / Equity (X)0.29
Asset Turnover Ratio (%)0.73

Syncom Formulations (India) Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual72.42
Total Current Assets Annual262.64
Non Current Assets Annual128.86
Total Shareholders Funds Annual286.45
Total Assets Annual391.50

Syncom Formulations (India) Ltd Earning Calls

EPS (INR)

Expected

0.19

Reported

0.16

Surprise

-15.79%

Dec 2024

EPS beaten by -15.79%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 33.33%

FAQS on Syncom Formulations (India) Ltd Financials

As of May 28, 2025, Syncom Formulations (India) Ltd has a market capitalization of 1,546.30 Cr. Value Research classifies it as a Small-Cap company.

Yes, Syncom Formulations (India) Ltd is with a debt-to-equity ratio of 0.01.

In FY 2024 , Syncom Formulations (India) Ltd recorded a total revenue of approximately 462.85 Cr marking a significant milestone in the company's financial performance.

Syncom Formulations (India) Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.5% and 0.4% annually, respectively..

Syncom Formulations (India) Ltd's current PE ratio is 31.64.

Syncom Formulations (India) Ltd's ROCE averaged 12.6% from the FY ending March 2023 to 2025, with a median of 10.1%. It peaked at 19.0% in March 2025, reflecting strong capital efficiency over the period..

Syncom Formulations (India) Ltd's latest EBIT is Rs. 65.51 Cr, surpassing the average EBIT of Rs. 43.81 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions